Federal contract award
75N95021F00001
LEAD OPTIMIZATION OF DOPAMINE D3 RECEPTOR ANTAGONIST FOR SUBSTANCE USE DISORDER (SUD).
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIDA |
| NAICS | 541715 — Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| PSC | AN11 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; BASIC RESEARCH |
| Parent award / vehicle | 75N95019D00031 |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $1.3M |
| Current contract value | $1.3M |
| Potential contract value / ceiling | $2.7M |
| Start date | Sep 26, 2021 |
| Current end date | Sep 25, 2022 |
| Potential end date | Sep 25, 2022 |
| Latest award activity | Aug 11, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 3 of 3 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 11, 2026 | P00002 | $-135.8K | LEAD OPTIMIZATION OF DOPAMINE D3 RECEPTOR ANTAGONIST FOR SUBSTANCE USE DISORDER (SUD) |
| Apr 21, 2026 | P00001 | $0 | TERMINATION FOR CONVENIENCE/TASK ORDER UNDER TERMINATED PARENT IDIQ LEAD OPTIMIZATION OF DOPAMINE D3 RECEPTOR ANTAGONIST FOR SUBSTANCE USE DISORDER (SUD) |
| Sep 24, 2021 | 0 | $1.4M | LEAD OPTIMIZATION OF DOPAMINE D3 RECEPTOR ANTAGONIST FOR SUBSTANCE USE DISORDER (SUD). |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.